

Antiretroviral Therapy Persistence Following a Change or Restart in Regimen Among People With HIV

Benjamin Chastek¹, Uche Mordi², Lisa B Le¹, Seojin Park², Cassidy Trom², Travis Lim², Mary J Christoph²

¹Optum, Eden Prairie, MN, USA; ²Gilead Sciences, Inc., Foster City, CA, USA

Copies of this poster obtained through QR (Quick Response) are for personal use only and may not be reproduced without written permission of the authors



Conclusions

- A greater percent of treatment-experienced (TE) people with HIV (PWH) restarting or switching to bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were persistent on treatment at 1 year compared with dolutegravir (DTG)-based regimens
- This finding was also observed among a subset of TE Medicare Advantage (MA) enrollees despite older age and greater burden of comorbidities
- Among MA enrollees, B/F/TAF had the lowest risk of nonpersistence overall compared with DTG-based regimens
- The study had several limitations, including challenges in capturing adherence data through medical claims for injectable therapy due to variations in days supplied (eg, 30 vs 60 days), potential biases with claims data, and lack of generalizability to the broader HIV population

Plain Language Summary

- This study looked at how long people with human immunodeficiency virus (HIV) stayed on their HIV medicine after switching to a new one or restarting treatment
- A higher percentage of people who took bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) stayed on therapy at 1 year compared with other therapies. This result was also seen in people with Medicare Advantage insurance
- People with HIV on B/F/TAF were more likely to stay on treatment over time than those taking other commonly used HIV medications

Introduction

- Discontinuation of antiretroviral therapy (ART) has been linked to poor outcomes for PWH.¹ Prior studies revealed that single-tablet regimens were associated with better adherence and lower risk of hospitalization compared to multi-tablet regimens among PWH²
- Understanding real-world treatment patterns among PWH and in key subgroups can support evidence-based decision-making, improve health outcomes, and reduce the economic burden of HIV
- Matching patients with the appropriate care could reduce the impact of suboptimal adherence on clinical outcomes

Objective


- Describe and compare regimen persistence for PWH after switching or restarting ART, overall and among MA enrollees

Methods

- This retrospective study utilized medical and pharmacy claims data from the Optum Research Database, including patients with commercial insurance or MA with Part D coverage
- PWH switching or restarting ART between July 1, 2017, and November 30, 2023, were included (**Figure 1**)
 - The index line of therapy was defined at the time of ART switch or restart
- Our primary outcome of nonpersistence was defined as the earliest of ART discontinuation (gap in all ART ≥90 days), switch, add-on, or death. Time to nonpersistence was defined as time until primary outcome, with censoring for end of continuous enrollment or study period
- Index regimens of interest were:
 - Bicitegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
 - Dolutegravir/lamivudine (DTG/3TC)
 - Dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)
 - Dolutegravir + emtricitabine/tenofovir alafenamide (DTG+F/TAF)
 - Dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF)
 - Cabotegravir + rilpivirine (CAB+RPV)
- Analysis was conducted in the overall TE population and among a subset enrolled in MA
- Inverse probability treatment weighting was implemented to adjust for demographic characteristics, baseline clinical measures, and baseline healthcare cost and utilization. Kaplan-Meier analysis was conducted after weighting to examine the effect of regimen selection on ART persistence at 1 year. Hazard ratios from Cox proportional hazard models were examined, controlling for residual differences in covariates for the entire follow-up period

Methods (Cont.)

Figure 1. Patient Observation Period




ART, antiretroviral therapy.

Results

Study Sample

- In total, 113,705 individuals had a diagnosis of HIV, and of those, 14,826 either switched or restarted one of the index regimens were eligible for the study (**Figure 2**). After weighting, mean age was 53 years, 20% of PWH were female, 44% were White, and 42% were enrolled in an MA plan (**Table 1**)
- The mean (SD) Quan-Charlson comorbidity score was 4.2 (2.2) for the overall sample and 5.0 (2.4) for the MA subgroup (**Table 1**)

Figure 2. Patient Sample Attrition



ID, identification.

Results (Cont.)

Table 1. Weighted Demographics and Clinical Characteristics by Index Regimen

	Total N = 14,826	B/F/TAF n = 8992	DTG/3TC n = 1771	DTG/ABC/3TC n = 2068	DTG+F/TAF n = 1296	DTG+F/TDF n = 217	CAB+RPV n = 482
Overall							
Age, years, mean (SD)	52.8 (13.0)	52.7 (13.0)	53.2 (13.3)	52.7 (12.9)	52.7 (13.1)	54.3 (14.0)	52.7 (13.3)
Age ≥ 50 years (%)	62.6	62.7	62.3	63.4	61.6	65.7	59.8
Female sex (%)	19.9	19.7	19.8	20.9	20.0	18.5	21.4
Race/ethnicity (%)							
White	44.3	44.4	43.3	44.4	43.9	43.7	46.1
Hispanic	13.5	13.8	13.5	12.0	13.8	14.7	12.3
Black	32.2	31.9	32.8	32.8	32.5	33.8	33.1
Asian	1.8	1.8	1.7	2.1	1.6	1.5	1.5
Charlson comorbidity index, mean (SD)	4.2 (2.2)	4.2 (2.2)	4.2 (2.2)	4.3 (2.2)	4.2 (2.2)	4.1 (2.1)	4.4 (2.0)
Comorbidities (%)							
Chronic kidney disease	13.9	13.9	14.1	13.5	14.1	15.0	14.8
Lipid disorders	42.5	42.2	42.3	42.5	42.5	42.9	46.4
Hepatitis B/C	7.1	6.9	6.8	7.7	7.2	6.4	7.3
Mental health disorders	32.9	32.8	32.0	33.2	33.4	35.7	35.4
Medicare Advantage	Total n = 6131	B/F/TAF n = 3708	DTG/3TC n = 744	DTG/ABC/3TC n = 799	DTG+F/TAF n = 532	DTG+F/TDF n = 80	CAB+RPV n = 268
Age, years, mean (SD)	61.3 (10.5)	61.2 (10.4)	62.1 (10.6)	61.1 (10.2)	60.6 (11.2)	61.7 (10.9)	62.3 (9.5)
Age ≥ 50 years (%)	86.7	86.8	87.4	86.4	84.0	85.9	89.9
Female sex (%)	30.2	29.8	32.0	32.7	29.6	16.4	30.2
Race/ethnicity (%)							
White	40.9	40.4	42.0	41.8	38.3	44.6	46.7
Hispanic	10.4	11.2	8.9	9.1	8.1	13.7	9.9
Black	38.9	38.6	39.1	38.2	43.0	36.4	35.3
Asian	0.9	1.0	1.0	0.7	0.8	0.0	0.4
Charlson comorbidity index, mean (SD)	5.0 (2.4)	4.9 (2.4)	5.1 (2.3)	5.1 (2.5)	5.0 (2.3)	4.6 (2.2)	5.0 (2.1)
Comorbidities (%)							
Chronic kidney disease	24.5	25.1	23.8	22.8	25.0	22.9	22.6
Lipid disorders	54.0	54.3	53.5	53.6	52.1	53.6	57.0
Hepatitis B/C	11.7	10.9	13.7	13.0	11.4	9.1	14.0
Mental health disorders	43.4	43.3	38.0	47.2	43.7	51.1	44.9

B/F/TAF, bicitegravir/emtricitabine/tenofovir alafenamide; CAB+RPV, cabotegravir + rilpivirine; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; DTG/3TC, dolutegravir/lamivudine; DTG+F/TAF, dolutegravir + emtricitabine/tenofovir alafenamide; DTG+F/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate; SD, standard deviation.

Index Line of Therapy: Duration

- B/F/TAF had the longest mean line of therapy duration (18.8 months) compared with other ARTs: DTG/ABC/3TC (17.7), DTG+F/TAF (17.0), DTG/3TC (13.7), CAB+RPV (8.9), and DTG+F/TDF (8.5) ($P < 0.05$)
- Duration was generally longer in the MA group: B/F/TAF (19.9 months), DTG/ABC/3TC (18.0), DTG+F/TAF (17.1), DTG/3TC (13.8), CAB+RPV (10.3), and DTG+F/TDF (9.4) ($P < 0.05$)

Index Line of Therapy: Adherence


- Compared with B/F/TAF (73.5%), the percentage of patients who were adherent (proportion of days covered [PDC] > 85%) was numerically similar for DTG/3TC (75.4%), CAB+RPV (71.2%), and DTG+F/TDF (65.8%). Adherence was significantly lower ($P < 0.05$) for DTG/ABC/3TC (69.7%) and DTG+F/TAF (66.5%)
- Compared with B/F/TAF (74.4%), the percentage of MA patients who were adherent (PDC > 85%) was not statistically different between DTG/3TC (74.5%), DTG+F/TDF (71.1%), and CAB+RPV (66.0%). Adherence was significantly lower ($P < 0.05$) for DTG+F/TAF (67.4%) and DTG/ABC/3TC (65.0%)

Persistence

- From weighted Kaplan-Meier analysis in the overall sample, the percentage of PWH persistent at 1 year was significantly greater ($P < 0.05$) for B/F/TAF versus DTG/3TC, DTG+F/TDF, DTG/ABC/3TC, DTG+F/TAF, and numerically greater but not statistically different versus CAB+RPV (**Figure 3**, **Table 2 left**), although comparisons cannot be reliably calculated with CAB+RPV due to the limited available sample size and variation with days supplied. Similar results were seen among MA beneficiaries (**Figures 4**, **Table 2 right**)
- Risk of nonpersistence was significantly greater ($P < 0.05$) for DTG/ABC/3TC, DTG+F/TAF, and DTG+F/TDF versus B/F/TAF in the overall population, and significantly greater ($P < 0.05$) for DTG-based regimens versus B/F/TAF in MA group (**Table 3**)


PWH persistent at 1 year were significantly greater ($P < 0.05$) for B/F/TAF versus DTG/3TC, DTG/ABC/3TC, DTG+F/TAF, and DTG+F/TDF

Figure 3. Weighted Kaplan-Meier Analysis of Persistence – Overall



B/F/TAF, bicitegravir/emtricitabine/tenofovir alafenamide; CAB+RPV, cabotegravir + rilpivirine; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; DTG/3TC, dolutegravir/lamivudine; DTG+F/TAF, dolutegravir + emtricitabine/tenofovir alafenamide; DTG+F/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate.

Figure 4. Weighted Kaplan-Meier Analysis of Persistence – Medicare Advantage



B/F/TAF, bicitegravir/emtricitabine/tenofovir alafenamide; CAB+RPV, cabotegravir + rilpivirine; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; DTG/3TC, dolutegravir/lamivudine; DTG+F/TAF, dolutegravir + emtricitabine/tenofovir alafenamide; DTG+F/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate.

Table 2. Weighted Kaplan-Meier Percent Persistent at 1 Year

	Overall			Medicare Advantage		
	%	P Value		%	P Value	
B/F/TAF	81.7	Ref.		79.1	Ref.	
DTG/3TC	78.3	0.011		74.0	0.024	
DTG/ABC/3TC	67.6	< 0.001		63.9	< 0.001	
DTG+F/TAF	64.5	< 0.001		59.0	< 0.001	
DTG+F/TDF	39.8	< 0.001		42.8	< 0.001	
CAB+RPV	75.5	0.063		75.7	0.513	

B/F/TAF, bicitegravir/emtricitabine/tenofovir alafenamide; CAB+RPV, cabotegravir + rilpivirine; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; DTG/3TC, dolutegravir/lamivudine; DTG+F/TAF, dolutegravir + emtricitabine/tenofovir alafenamide; DTG+F/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate.

Table 3. Adjusted Weighted Proportional Hazard Model of Persistence

	Index Regimen	Hazard Ratio (95% CI)	P Value
Overall	B/F/TAF	Ref.	-
	DTG/3TC	1.08 (0.94-1.25)	0.298
	DTG/ABC/3TC	1.74 (1.58-1.92)	< 0.001
	DTG+F/TAF	1.99 (1.80-2.20)	< 0.001
	DTG+F/TDF	5.01 (4.15-6.06)	< 0.001
	CAB+RPV	1.23 (0.87-1.73)	0.234
Medicare Advantage	B/F/TAF	Ref.	-
	DTG/3TC	1.26 (1.03-1.53)	0.023
	DTG/ABC/3TC	1.89 (1.64-2.17)	< 0.001
	DTG+F/TAF	2.12 (1.83-2.45)	< 0.001
	DTG+F/TDF	4.47 (3.35-5.97)	< 0.001
	CAB+RPV	1.12 (0.68-1.84)	0.660

B/F/TAF, bicitegravir/emtricitabine/tenofovir alafenamide; CAB+RPV, cabotegravir + rilpivirine; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; DTG/3TC, dolutegravir/lamivudine; DTG+F/TAF, dolutegravir + emtricitabine/tenofovir alafenamide; DTG+F/TDF, dolutegravir + emtricitabine/tenofovir disoproxil fumarate.